==== Reference: Usmani SS, Bedi G, Samuel JS, Singh S, Kalra S, Kumar P, et al. (2017) THPdb: Database of FDA-approved peptide and protein therapeutics. PLoS ONE 12(7) e0181748.====

Detailed description page of THPdb

This page displays user query in tabular form.

1798 details
Primary information
ThPP IDTh1192
Therapeutic Peptide/Protein NameUstekinumab
SequenceNA view full sequnce in fasta
Functional ClassificationIIIb
Molecular Weight14690
Chemical FormulaNA
Isoelectric PointNA
HydrophobicityNA
Melting Point (℃)NA
Half LifeNA
DescriptionCNTO 1275 is the experimental name for the human immunosuppressive drug ustekinumab developed by the biotechnology company Centocor. It is a laboratory manufactured, monoclonal antibody directed against interleukins IL-12 and IL-23.
Indication/DiseaseFor treatment in psoriasis and psoriatic disorders.
PharmacodynamicsNA
Mechanism of ActionSimilar to the immunosuppressive function of Etanercept (Enbrel), CNTO 1275 is designed to interfere with the triggering of the body's inflamatory response through the suppression of certain cytokines. Specifically, CNTO 1275 blocks interleukin IL-12 and IL-23 (via the p40 subunit of IL-12 and IL-23) which help activate certain T-cells.
ToxicityNA
MetabolismNA
AbsorptionNA
Volume of DistributionNA
ClearanceNA
CategoriesDeramtologic agent, Immunosuppressive agent, antineoplastic agent
Patents Number
Date of Issue
Date of Expiry
Drug InteractionBelimumab, Denosumab, Infliximab, Leflunomide, Natalizumab, Pimecrolimus, Roflumilast, Sipuleucel-T, Tacrolimus, Tofacitinib, Trastuzumab
TargetInterleukin-12 subunit beta
Information of corresponding available drug in the market
Brand NameStelara
CompanyJanssen Biotech, Inc.
Brand DiscriptionSTELARA is a human IgG1κ monoclonal antibody against the p40 subunit of the IL-12 and IL23 cytokines. Using DNA recombinant technology, STELARA® is produced in a well characterized recombinant cell line and is purified using standard bio-processing technology. The manufacturing process contains steps for the clearance of viruses. STELARA® is comprised of 1326 amino acids
Prescribed forPsoriasis (Ps) and Psoriatic Arthritis (PsA)
Chemical NameNA
FormulationEach 45 mg ustekinumab prefilled syringe also contains: L-histidine and L-histidine monohydrochloride monohydrate (0.5 mg), Polysorbate 80 (0.02 mg), and sucrose (38 mg) to fill to a final volume of 0.5 mL.
Physcial Appearncesolution fro injection
Route of AdministrationSubcutaneous
Recommended DosageIn case of psoriasis, for patients weighing ≤ 100 kg (220 lbs), the recommended dose is 45 mg initially and 4 weeks later, followed by 45 mg every 12 weeks. In case of Psoriatic Arthritis ecommended dose is 45 mg initially and 4 weeks later, followed by 45 mg every 12 weeks.
ContraindicationNA
Side EffectsAdverse reactions that occurred at rates less than 1% in the controlled period of Ps STUDIES 1 and 2 through week 12 included: cellulitis, herpes zoster, diverticulitis and certain injection site reaction
Useful Linkhttp://www.rxlist.com/stelara-drug.htm
PubMed ID25633241, 24997741, 19222517, 26432476, 26607958, 25284845, 22531442, 22171583, 22168335
3-D StructureN.A.